Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Account Payables (2016 - 2025)

Avalo Therapeutics' Change in Account Payables history spans 12 years, with the latest figure at -$337000.0 for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 77.95% year-over-year to -$337000.0; the TTM value through Dec 2025 reached -$146000.0, up 10.43%, while the annual FY2025 figure was -$146000.0, 10.43% up from the prior year.
  • Change in Account Payables reached -$337000.0 in Q4 2025 per AVTX's latest filing, up from -$1.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.3 million in Q1 2021 to a low of -$9.7 million in Q2 2021.
  • Average Change in Account Payables over 5 years is -$121800.0, with a median of -$80500.0 recorded in 2021.
  • The largest YoY upside for Change in Account Payables was 3620.72% in 2021 against a maximum downside of 5651.79% in 2021.
  • A 5-year view of Change in Account Payables shows it stood at -$198000.0 in 2021, then skyrocketed by 824.75% to $1.4 million in 2022, then tumbled by 123.83% to -$342000.0 in 2023, then plummeted by 346.78% to -$1.5 million in 2024, then surged by 77.95% to -$337000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Change in Account Payables are -$337000.0 (Q4 2025), -$1.9 million (Q3 2025), and $1.7 million (Q2 2025).